Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-2.48 Insider Own1.90% Shs Outstand37.19M Perf Week-3.86%
Market Cap2.79B Forward P/E- EPS next Y-3.29 Insider Trans-17.41% Shs Float32.36M Perf Month19.07%
Income-92.30M PEG- EPS next Q-0.75 Inst Own76.40% Short Float6.81% Perf Quarter25.25%
Sales8.90M P/S313.40 EPS this Y22.10% Inst Trans1.65% Short Ratio3.32 Perf Half Y189.58%
Book/sh4.17 P/B17.99 EPS next Y-7.90% ROA-32.60% Target Price84.62 Perf Year107.30%
Cash/sh5.61 P/C13.36 EPS next 5Y- ROE-48.90% 52W Range21.98 - 82.49 Perf YTD160.24%
Dividend- P/FCF- EPS past 5Y1.20% ROI-41.10% 52W High-9.08% Beta1.10
Dividend %- Quick Ratio9.50 Sales past 5Y30.80% Gross Margin- 52W Low241.22% ATR5.11
Employees212 Current Ratio9.50 Sales Q/Q-68.60% Oper. Margin- RSI (14)55.71 Volatility5.85% 7.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-24.40% Profit Margin- Rel Volume1.30 Prev Close74.61
ShortableYes LT Debt/Eq0.23 EarningsJul 29 BMO Payout- Avg Volume663.90K Price75.00
Recom1.50 SMA205.26% SMA5018.24% SMA20069.31% Volume861,086 Change0.52%
Apr-12-19Initiated Piper Jaffray Overweight $80
Mar-29-19Initiated Robert W. Baird Outperform $85
Mar-04-19Reiterated Chardan Capital Markets Buy $70 → $100
Feb-25-19Reiterated Cantor Fitzgerald Overweight $68 → $81
Feb-11-19Reiterated H.C. Wainwright Buy $60 → $73
Dec-31-18Resumed B. Riley FBR Buy $72
Nov-26-18Reiterated H.C. Wainwright Buy $48 → $60
Jul-27-18Initiated Cantor Fitzgerald Overweight $58
Jun-28-18Initiated B. Riley FBR, Inc. Buy $50
May-16-18Initiated Wells Fargo Outperform $47
May-07-18Reiterated Leerink Partners Outperform $26 → $63
Jan-04-18Initiated Janney Buy $25
Dec-01-17Initiated H.C. Wainwright Buy $28
Nov-07-17Initiated Evercore ISI Outperform $22
Oct-20-17Reiterated Leerink Partners Outperform $17 → $19
Dec-06-16Reiterated WallachBeth Buy $27 → $15
Nov-22-16Downgrade Jefferies Buy → Hold
Nov-16-16Downgrade Piper Jaffray Overweight → Neutral
Aug-04-16Resumed H.C. Wainwright Buy $21
Jun-15-16Reiterated WallachBeth Buy $60 → $35
Jun-22-19 09:33PM  Hedge Funds Have Never Been This Bullish On Uniqure NV (QURE) Insider Monkey
Jun-21-19 07:00AM  uniQure Announces Presentations at the Upcoming 27th Congress of the International Society on Thrombosis and Haemostasis (ISTH) GlobeNewswire
Jun-20-19 09:41AM  The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure Zacks
Jun-19-19 11:20AM  Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal Zacks
Jun-18-19 09:15AM  Fed Week Begins in the Green Zacks
Jun-17-19 04:21PM  Why This Gene Therapy Stock Looks Like A Sure Takeover Bet: Analyst Investor's Business Daily +11.84%
09:41AM  Gene-Therapy Firm UniQure Explores Options Including Sale Bloomberg
09:33AM  UniQure Jumps on Report It's Exploring a Possible Sale TheStreet.com
Jun-11-19 08:47AM  Is the Options Market Predicting a Spike in uniQure (QURE) Stock? Zacks -12.02%
Jun-05-19 11:53AM  AMD and 3 more momentum stocks to watch MarketWatch
07:08AM  An Intrinsic Calculation For uniQure N.V. (NASDAQ:QURE) Suggests It's 29% Undervalued Simply Wall St.
Jun-04-19 09:01AM  uniQure (QURE) Jumps: Stock Rises 8.9% Zacks +9.44%
May-31-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-22-19 07:00AM  uniQure Strengthens Intellectual Property Portfolio with Granted Patent Claims Covering AMT-130 for Huntingtons Disease GlobeNewswire
May-10-19 04:16PM  This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study Investor's Business Daily +6.67%
02:44PM  uniQure N.V. (NASDAQ:QURE) Insiders Have Been Selling Simply Wall St.
08:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
May-07-19 07:00AM  uniQure Announces Featured Presentations of New Data on Spinocerebellar Ataxia Type 3 at the 2019 American Academy of Neurology Annual Meeting GlobeNewswire
May-02-19 04:26PM  Did Hedge Funds Drop The Ball On Uniqure NV (QURE) ? Insider Monkey
07:00AM  uniQure Announces New Preclinical Data in Hemophilia A and Fabry Disease in Oral Presentations at the 22nd ASGCT Annual Meeting GlobeNewswire
May-01-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Apr-29-19 07:07AM  UniQure: 1Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces First Quarter 2019 Results and Highlights Recent Company Progress GlobeNewswire
Apr-15-19 12:15PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire
08:43AM  Want an insiders way to play IPOs? This fund has had outsize success with its strategy MarketWatch
Apr-08-19 09:45AM  4 Gene Therapy Players Likely to Become Buyout Targets in 2019 Zacks
07:00AM  uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntingtons Disease GlobeNewswire
Apr-04-19 02:36PM  uniQure N.V. (NASDAQ:QURE): Financial Strength Analysis Simply Wall St. +5.86%
Mar-29-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-01-19 09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com +6.15%
07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Feb-28-19 07:00AM  uniQure Announces 2018 Financial Results and Highlights Recent Company Progress GlobeNewswire
Feb-27-19 09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
07:00AM  uniQure Presents New Preclinical Data on AMT-130 at the CHDIs 14th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
09:15AM  Deal on the Way Now that Deadline is Delayed? Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
07:19AM  2 More Gene Therapy Stocks on Big Pharma's Buyout Radar Motley Fool
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga +34.30%
Feb-22-19 07:45AM  Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences Discovering Underlying Factors of Influence GlobeNewswire
Feb-15-19 07:24AM  uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids GlobeNewswire
Feb-13-19 10:29AM  How Does Investing In uniQure N.V. (NASDAQ:QURE) Impact The Volatility Of Your Portfolio? Simply Wall St. -5.88%
Feb-08-19 07:26AM  UniQure gene therapy shows rise in blood-clotting protein in trial Reuters +9.98%
07:00AM  uniQure Announces Updated Clinical Data from Phase IIb Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Feb-04-19 07:00AM  uniQure Announces First Patient Treated in HOPE-B Pivotal Trial of AMT-061 in Patients with Hemophilia B GlobeNewswire
Jan-30-19 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Jan-22-19 07:00AM  uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-130 in Huntingtons Disease GlobeNewswire
Dec-18-18 02:13AM  Uniqure NV (QURE): Hedge Fund Sentiment Unchanged Insider Monkey
Dec-12-18 10:14AM  Do Institutions Own uniQure N.V. (NASDAQ:QURE) Shares? Simply Wall St.
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks
Dec-03-18 07:00AM  uniQure Announces Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 and Confirms Dose for AMT-061 Pivotal Study in Hemophilia B GlobeNewswire
Nov-30-18 08:00AM  Analysis: Positioning to Benefit within Vivint Solar, uniQure N.V, Internap, Intuit, WideOpenWest, and Deere Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-29-18 01:39PM  Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma Investor's Business Daily
Nov-23-18 06:57AM  Novartis Gets Approval for Gene Therapy Luxturna in Europe Zacks
Nov-19-18 12:15PM  uniQure Highlights Pipeline Expansion and Advancements in Technology at Research & Development Day GlobeNewswire -9.11%
Nov-16-18 12:45PM  Uniqure CEO discusses company's positive data in hemophil... CNBC Videos
08:35AM  uniQure Up on Positive Data From Mid-Stage Hemophilia Study Zacks
Nov-15-18 11:59AM  Why uniQure N.V. Stock Is Skyrocketing Today Motley Fool +35.66%
07:00AM  uniQure Announces Initial Topline Data from Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Nov-13-18 08:45AM  Options Traders Expect Huge Moves in uniQure (QURE) Stock Zacks
Nov-06-18 08:35AM  UniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:27AM  UniQure: 3Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces Third Quarter 2018 Financial Results and Highlights Company Progress GlobeNewswire
Nov-05-18 07:00AM  uniQure to Host Research & Development Day on Monday, November 19 in New York City GlobeNewswire
Oct-31-18 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Oct-23-18 07:45AM  Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-18-18 06:55AM  uniQure Announces Development of a Highly Potent, Next-Generation Promoter for Liver-Directed Gene Therapies GlobeNewswire
Oct-17-18 07:00AM  uniQure Presents New Data Demonstrating Its Large-Scale Manufacturing Capabilities at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting GlobeNewswire
Oct-16-18 07:00AM  uniQure Announces Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT) GlobeNewswire
Sep-28-18 07:00AM  uniQure to Participate in Multiple Upcoming Industry Conferences GlobeNewswire
Sep-24-18 07:00AM  uniQure Provides Update on Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Sep-13-18 08:50AM  Implied Volatility Surging for uniQure (QURE) Stock Options Zacks
Sep-10-18 06:00AM  Achillion Appoints Paul Firuta Chief Operating Officer GlobeNewswire
Aug-30-18 07:00AM  uniQure to Participate at Multiple Upcoming Conferences GlobeNewswire
Aug-27-18 12:14PM  Play The Future of Gene Therapy With These 5 Biotech Stocks InvestorPlace
Aug-23-18 07:00AM  uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Aug-21-18 08:30AM  Report: Exploring Fundamental Drivers Behind Oaktree Specialty Lending, uniQure N.V, Mercury, Akebia Therapeutics, Mitel Networks, and Greenlight Capital Re New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-08-18 08:40AM  UniQure (QURE) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:34AM  UniQure: 2Q Earnings Snapshot Associated Press
07:00AM  uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress GlobeNewswire
Jul-13-18 03:35PM  3 Gene Therapy Companies In Hot Pursuit Of A 'One-And-Done' Cure Investor's Business Daily
Jun-28-18 03:18PM  3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy Benzinga +13.58%
07:00AM  uniQure Enrolls First Patient in Phase III HOPE-B Pivotal Study of AMT-061 in Patients with Hemophilia B GlobeNewswire
Jun-25-18 08:49AM  Are These 3 Red-Hot Gene Therapy Stocks Still Buys? Motley Fool
Jun-13-18 07:00AM  uniQure Announces New Appointments to its Board of Directors GlobeNewswire
Jun-06-18 08:30AM  Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure N.V, Retail Opportunity Investments, and GDS Holdings Limited Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-29-18 07:00AM  uniQure Announces the Issuance of New Patents Providing Broad Protection of the Padua Variant of Factor IX in Gene Therapy GlobeNewswire
May-22-18 07:25AM  Wired News - uniQure Announced Presentation of Preclinical Data Demonstrating Advances in Distribution of Gene Therapy at ASGCT Annual Meeting in Chicago ACCESSWIRE
May-21-18 07:00AM  uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies GlobeNewswire
May-20-18 04:38PM  Uniqure Notches Bullish Initiation On Gene Therapy Prospects Benzinga
May-18-18 07:00AM  uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene Therapy GlobeNewswire
May-14-18 07:00AM  3 Cutting-Edge Biotech Stocks That Can Double in Value TheStreet.com
May-09-18 03:05PM  3 High-Growth Stocks That Could Soar Motley Fool +5.27%
May-07-18 11:47AM  uniQure Announces Closing Of Public Offering And Full Exercise Of The Underwriters' Option To Purchase Additional Shares GlobeNewswire
May-04-18 08:00AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
May-02-18 07:32PM  uniQure Announces Pricing of its Public Offering GlobeNewswire
May-01-18 04:04PM  uniQure Announces Proposed Public Offering GlobeNewswire
Apr-30-18 12:00PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, CFO, Managing DirectorJun 19Sale77.458,000619,626407,230Jun 20 11:03 AM
Astley-Sparke PhilipDirectorJun 03Sale63.636,000381,77913,272Jun 04 02:07 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMay 15Sale58.388,000467,017415,230May 17 03:48 PM
KLEMT CHRISTIANChief Accounting OfficerApr 16Sale57.181,54688,40054,539Apr 17 11:09 AM
Astley-Sparke PhilipDirectorApr 01Sale59.846,000359,04019,272Apr 03 12:22 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 14Sale63.0919,6881,242,081423,230Mar 15 03:15 PM
Kapusta Matthew CCEO, CFO, Managing DirectorMar 13Sale64.3247,6883,067,216442,918Mar 15 03:15 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsFeb 15Option Exercise5.3120,000106,20046,578Feb 20 02:18 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsFeb 15Sale35.828,000286,56038,578Feb 20 02:18 PM
Kaye JackDirectorJan 28Sale31.311,21037,88514,934Jan 31 05:19 PM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 28Sale31.4219,085599,651490,028Jan 30 07:15 PM
Balachandran MadhavanDirectorJan 28Sale31.311,21037,8856,812Jan 30 05:32 PM
Soteropoulos PaulaDirectorJan 28Sale31.321,21037,89719,934Jan 30 05:28 PM
SCHAFFER DAVIDDirectorJan 28Sale31.311,21037,88545,721Jan 30 05:24 PM
Astley-Sparke PhilipDirectorJan 28Sale31.321,21037,89725,272Jan 30 05:20 PM
van Deventer SanderChief Scientific OfficerJan 28Sale31.311,35842,51940,313Jan 30 05:01 PM
KLEMT CHRISTIANChief Accounting OfficerJan 28Sale31.291,47946,27856,085Jan 30 04:57 PM
Kuta Alexander Edward IIISVP, Regulatory AffairsJan 28Sale31.291,05232,91726,578Jan 30 04:55 PM
McMillan Scott T.Chief Operating OfficerJan 28Sale31.2359118,45720,432Jan 30 04:52 PM
Springhorn Jeremy P.DirectorJan 28Sale31.321,21037,8976,812Jan 30 04:49 PM
SCHAFFER DAVIDDirectorJan 17Sale30.717,500230,32543,701Jan 29 08:32 PM
KLEMT CHRISTIANChief Accounting OfficerJan 03Sale27.915,739160,17540,000Jan 07 11:21 AM
Astley-Sparke PhilipDirectorDec 03Sale30.395,000151,95023,252Dec 06 09:38 AM